A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine

Chinese Medical Journal

Volumn 122, Issue 14, 2009, Pages 1655-1659

  Huang, Yang ^a,b   Qiu, Chao ^b   Liu, Lian Xing ^a   Feng, Yan Meng ^a   Zhu, Ting ^a   Xu, Jian Qing ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Human immunodeficiency virus type 1; Luciferase; Mice model; Vaccine

Indexed keywords

FIREFLY LUCIFERASE; GAG PROTEIN; PLASMID DNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INOCULATION; MOUSE; NONHUMAN; OVARY; POXVIRUS; PROTEIN EXPRESSION; TIANTAN VACCINIA; UTERINE CERVIX; UTERUS; VACCINIA; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LUCIFERASES; MICE; MICE, INBRED BALB C; POXVIRIDAE; RECOMBINANT PROTEINS; VIRUS REPLICATION;

EID: 70349554060     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.14.010     Document Type: Article

References (20)

1. Kumar A, Narayan O. Immunization for long-term protection against AIDS using the macaque model. Virology 2001; 285: 1-5.
2. Locher CP, Witt SA, Herndier BG, Tenner-Racz K, Racz P, Levy JA. Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development. Immunol Rev 2001; 183: 127-140.
3. Boberg A, Bråve A, Johansson S, Wahren B, Hinkula J, Rollman E. Murine model for HIV vaccination and challenge. Expert Rev Vaccines 2008; 7: 117-130.
4. Saxon A, Macy E, Denis K, Tary-Lehmann M, Witte O, Braun J. Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J Clin Invest 1991; 87: 658-665.
5. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256-259.
6. Borkow G. Mouse models for HIV-1 infection. IUBMB Life 2005; 57: 819-823.
7. Garcia S, Dadaglio G, Gougeon ML. Limits of the human-PBL-SCID mice model: Severe restriction of the V beta T-cell repertoire of engrafted human T cells. Blood 1997; 89: 329-336.
8. Tary-Lehmann M, Saxon A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J Exp Med 1992; 175: 503-516.
9. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A 1998; 95: 1709-1714.
10. Shinoda K, Xin KQ, Okuda K. A modified HIV challenge assay in mice by using luciferase-expressing vaccinia virus. Vaccine 2006; 24: 2751-2754.
11. Rodriguez JF, Rodriguez D, Rodriguez JR, McGowan EB, Esteban M. Expression of the firefly luciferase gene in vaccinia virus: A highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc Natl Acad Sci U S A 1988; 85: 1667-1671.
12. Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, Gonzalez-Aseguinolaza G, Esteban M. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 2007; 88: 2473-2478.
13. Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003; 148: 827-839.
14. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000; 74: 923-933.
15. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, Chen IS, et al. The SCID-hu mouse as a model for HIV-1 infection. Nature 1993; 363: 732-736.
16. + T cell depletion and viral replication in SIV infection. Science 1998; 280: 427-431.
17. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200: 761-770.
18. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006; 3: e484.
19. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1: 23-30.
20. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80: 8236-8247.